[1. Lee R, Margaritis M, Channon KM, et al. Evaluating oxidative stress in human cardiovascular disease: methodological aspects and considerations. Curr Med Chem. 2012;19:2504-20.10.2174/092986712800493057341220422489713]Search in Google Scholar
[2. Tousoulis D, Psarros C, Demosthenous M, et al. Innate and adaptive inflammation as a therapeutic target in vascular disease: the emerging role of statins. J Am Coll Cardiol. 2014;63:2491-502.10.1016/j.jacc.2014.01.05424613322]Search in Google Scholar
[3. Psarros C, Lee R, Margaritis M, et al. Nanomedicine for the prevention, treatment and imaging of atherosclerosis. Nanomedicine. 2012;8 Suppl 1:S59-68.10.1016/j.nano.2012.05.00622640906]Search in Google Scholar
[4. Antoniades C, Antonopoulos AS, Tousoulis D, et al. Adiponectin: from obesity to cardiovascular disease. Obes Rev. 2009;10:269-79.10.1111/j.1467-789X.2009.00571.x19389061]Search in Google Scholar
[5. Antonopoulos AS, Lee R, Margaritis M, et al. Adiponectin as a regulator of vascular redox state: therapeutic implications. Recent Pat Cardiovasc Drug Discov. 2011;6:78-88.10.2174/15748901179593383721453253]Search in Google Scholar
[6. Margaritis M, Antonopoulos AS, Digby J, et al. Interactions between vascular wall and perivascular adipose tissue reveal novel roles for adiponectin in the regulation of endothelial nitric oxide synthase function in human vessels. Circulation. 2013;127:2209-21.10.1161/CIRCULATIONAHA.112.00113323625959]Search in Google Scholar
[7. Antonopoulos AS, Margaritis M, Coutinho P, et al. Adiponectin As A Link Between Type 2 Diabetes Mellitus And Vascular NADPH-Oxidase Activity In The Human Arterial Wall: The Regulatory Role Of Perivascular Adipose Tissue. Diabetes. 2014. doi: 10.2337/db14-1011 [Epub ahead of print]10.2337/db14-101125552596]Search in Google Scholar
[8. Channon KM and Guzik TJ. Mechanisms of superoxide production in human blood vessels: relationship to endothelial dysfunction, clinical and genetic risk factors. J Physiol Pharmacol. 2002;53:515-24.]Search in Google Scholar
[9. Alp NJ, Mussa S, Khoo J, et al. Tetrahydrobiopterin-dependent preservation of nitric oxide-mediated endothelial function in diabetes by targeted transgenic GTP-cyclohydrolase I overexpression. J Clin Invest. 2003;112:725-35.10.1172/JCI1778618219612952921]Search in Google Scholar
[10. Cunnington C, Van Assche T, Shirodaria C, et al. Systemic and Vascular Oxidation Limits the Efficacy of Oral Tetrahydrobiopterin Treatment in Patients With Coronary Artery Disease. Circulation. 2012;125:1356-66.10.1161/CIRCULATIONAHA.111.038919523893522315282]Search in Google Scholar
[11. Landmesser U, Hornig B, Drexler H. Endothelial function: a critical determinant in atherosclerosis? Circulation. 2004;109:II27-33.10.1161/01.CIR.0000129501.88485.1f15173060]Search in Google Scholar
[12. Antoniades C, Tousoulis D, Vasiliadou C, et al. Genetic polymorphism on endothelial nitric oxide synthase affects endothelial activation and inflammatory response during the acute phase of myocardial infarction. J Am Coll Cardiol. 2005;46:1101-9.10.1016/j.jacc.2005.05.072]Search in Google Scholar
[13. Antoniades C, Shirodaria C, Warrick N, et al. 5-methyltetrahydrofolate rapidly improves endothelial function and decreases superoxide production in human vessels: effects on vascular tetrahydrobiopterin availability and endothelial nitric oxide synthase coupling. Circulation. 2006;114:1193-201.10.1161/CIRCULATIONAHA.106.612325]Search in Google Scholar
[14. Antoniades C, Shirodaria C, Leeson P, et al. Association of plasma asymmetrical dimethylarginine (ADMA) with elevated vascular superoxide production and endothelial nitric oxide synthase uncoupling: implications for endothelial function in human atherosclerosis. Eur Heart J. 2009;30:1142-50.10.1093/eurheartj/ehp061]Search in Google Scholar
[15. Gounari P, Tousoulis D, Antoniades C, et al. Rosuvastatin but not ezetimibe improves endothelial function in patients with heart failure, by mechanisms independent of lipid lowering. Int J Cardiol. 2010;142:87-91.10.1016/j.ijcard.2008.12.067]Search in Google Scholar
[16. Antoniades C, Demosthenous M, Tousoulis D, et al. Role of asymmetrical dimethylarginine in inflammation-induced endothelial dysfunction in human atherosclerosis. Hypertension. 2011;58:93-8.10.1161/HYPERTENSIONAHA.110.168245]Search in Google Scholar
[17. Ait-Oufella H, Taleb S, Mallat Z, et al. Recent advances on the role of cytokines in atherosclerosis. Arterioscler Thromb Vasc Biol. 2011;31:969-79.10.1161/ATVBAHA.110.207415]Search in Google Scholar
[18. Tousoulis D, Antoniades C, Stefanadis C. Assessing inflammatory status in cardiovascular disease. Heart. 2007;93:1001-7.10.1136/hrt.2006.088211]Search in Google Scholar
[19. Kim JH, Bachmann RA, Chen J. Interleukin-6 and insulin resistance. Vitam Horm. 2009;80:613-33.10.1016/S0083-6729(08)00621-3]Search in Google Scholar
[20. Schuett H, Luchtefeld M, Grothusen C, et al. How much is too much? Interleukin-6 and its signalling in atherosclerosis. Thromb Haemost. 2009;102:215-22.10.1160/TH09-05-029719652871]Search in Google Scholar
[21. Abeywardena MY, Leifert WR, Warnes KE, et al. Cardiovascular biology of interleukin-6. Curr Pharm Des. 2009;15:1809-21.10.2174/13816120978818629019442192]Search in Google Scholar
[22. Yudkin JS, Kumari M, Humphries SE, et al. Inflammation, obesity, stress and coronary heart disease: is interleukin-6 the link? Atherosclerosis. 2000;148:209-14.]Search in Google Scholar
[23. Hartge MM, Unger T, Kintscher U. The endothelium and vascular inflammation in diabetes. Diab Vasc Dis Res. 2007;4:84-8.10.3132/dvdr.2007.025]Search in Google Scholar
[24. Wang Z, Castresana MR, Newman WH. Reactive oxygen and NFkappaB in VEGF-induced migration of human vascular smooth muscle cells. Biochem Biophys Res Commun. 2001;285:669-74.10.1006/bbrc.2001.5232]Search in Google Scholar
[25. Church LD, Cook GP, McDermott MF. Primer: inflammasomes and interleukin 1beta in inflammatory disorders. Nat Clin Pract Rheumatol. 2008;4:34-42.10.1038/ncprheum0681]Search in Google Scholar
[26. Schmitz J, Owyang A, Oldham E, et al. IL-33, an interleukin-1-like cytokine that signals via the IL-1 receptor-related protein ST2 and induces T helper type 2-associated cytokines. Immunity. 2005;23:479-90.10.1016/j.immuni.2005.09.015]Search in Google Scholar
[27. Okamura H, Tsutsui H, Kashiwamura S, et al. Interleukin-18: a novel cytokine that augments both innate and acquired immunity. Adv Immunol. 1998;70:281-312.10.1016/S0065-2776(08)60389-2]Search in Google Scholar
[28. Pizarro TT, Cominelli F. Cloning IL-1 and the birth of a new era in cytokine biology. J Immunol. 2007;178:5411-2.10.4049/jimmunol.178.9.541117442919]Search in Google Scholar
[29. Asadullah K, Sterry W, Volk HD. Interleukin-10 therapy--review of a new approach. Pharmacol Rev. 2003;55:241-69.10.1124/pr.55.2.412773629]Search in Google Scholar
[30. Han X, Kitamoto S, Wang H, et al. Interleukin-10 overexpression in macrophages suppresses atherosclerosis in hyperlipidemic mice. FASEB J. 2010;24:2869-80.10.1096/fj.09-148155290928320354139]Search in Google Scholar
[31. Han X, Kitamoto S, Lian Q, et al. Interleukin-10 facilitates both cholesterol uptake and efflux in macrophages. J Biol Chem. 2009;284:32950-8.10.1074/jbc.M109.040899278171019776020]Search in Google Scholar
[32. Gracie JA, Robertson SE, McInnes IB. Interleukin-18. J Leukoc Biol. 2003;73:213-24.10.1189/jlb.060231312554798]Search in Google Scholar
[33. Blankenberg S, Tiret L, Bickel C, et al. Interleukin-18 is a strong predictor of cardiovascular death in stable and unstable angina. Circulation. 2002;106:24-30.10.1161/01.CIR.0000020546.30940.92]Search in Google Scholar
[34. Tziakas DN, Chalikias GK, Kaski JC, et al. Inflammatory and anti-inflammatory variable clusters and risk prediction in acute coronary syndrome patients: a factor analysis approach. Atherosclerosis. 2007;193:196-203.10.1016/j.atherosclerosis.2006.06.016]Search in Google Scholar
[35. Lin S, Lee CK, Wang YM, et al. Measurement of dimensions of pentagonal doughnut-shaped C-reactive protein using an atomic force microscope and a dual polarisation interferometric biosensor. Biosens Bioelectron. 2006;22:323-7.10.1016/j.bios.2006.01.018]Search in Google Scholar
[36. Calabro P, Willerson JT, Yeh ET. Inflammatory cytokines stimulated C-reactive protein production by human coronary artery smooth muscle cells. Circulation. 2003;108:1930-2. 10.1161/01.CIR.0000096055.62724.C5]Search in Google Scholar
[37. Venugopal SK, Devaraj S, Jialal I. Macrophage conditioned medium induces the expression of C-reactive protein in human aortic endothelial cells: potential for paracrine/autocrine effects. Am J Pathol. 2005;166:1265-71.10.1016/S0002-9440(10)62345-0]Search in Google Scholar
[38. Pepys MB, Hirschfield GM. C-reactive protein: a critical update. J Clin Invest. 2003;111:1805-12.10.1172/JCI200318921]Search in Google Scholar
[39. Rifai N, Ridker PM. Proposed cardiovascular risk assessment algorithm using high-sensitivity C-reactive protein and lipid screening. Clin Chem. 2001;47:28-30.10.1093/clinchem/47.1.28]Search in Google Scholar
[40. Elkind MS. Inflammation, atherosclerosis, and stroke. Neurologist. 2006;12:140-8.10.1097/01.nrl.0000215789.70804.b016688015]Search in Google Scholar
[41. King VL, Thompson J, Tannock LR. Serum amyloid A in atherosclerosis. Curr Opin Lipidol. 2011;22:302-7.10.1097/MOL.0b013e3283488c3921734573]Search in Google Scholar
[42. Rho YH, Chung CP, Oeser A, et al. Novel cardiovascular risk factors in premature coronary atherosclerosis associated with systemic lupus erythematosus. J Rheumatol. 2008;35:1789-94.]Search in Google Scholar
[43. Min JH, Jain MK, Wilder C, et al. Membrane-bound plasma platelet activating factor acetylhydrolase acts on substrate in the aqueous phase. Biochemistry. 1999;38:12935-42.10.1021/bi991149u10504265]Search in Google Scholar
[44. Wilensky RL and Macphee CH. Lipoprotein-associated phospholipase A(2) and atherosclerosis. Curr Opin Lipidol. 2009;20:415-20.10.1097/MOL.0b013e3283307c16]Search in Google Scholar
[45. Anderson JL. Lipoprotein-associated phospholipase A2: an independent predictor of coronary artery disease events in primary and secondary prevention. Am J Cardiol. 2008;101:23F-33F.10.1016/j.amjcard.2008.04.015]Search in Google Scholar
[46. Blankenberg S, Barbaux S, Tiret L. Adhesion molecules and atherosclerosis. Atherosclerosis. 2003;170:191-203.10.1016/S0021-9150(03)00097-2]Search in Google Scholar
[47. McEver RP. Selectins: lectins that initiate cell adhesion under flow. Curr Opin Cell Biol. 2002;14:581-6.10.1016/S0955-0674(02)00367-8]Search in Google Scholar
[48. Galkina E, Kadl A, Sanders J, et al. Lymphocyte recruitment into the aortic wall before and during development of atherosclerosis is partially L-selectin dependent. J Exp Med. 2006;203:1273-82.10.1084/jem.20052205212120816682495]Search in Google Scholar
[49. Eriksson EE, Xie X, Werr J, et al. Importance of primary capture and L-selectin-dependent secondary capture in leukocyte accumulation in inflammation and atherosclerosis in vivo. J Exp Med. 2001;194:205-18.10.1084/jem.194.2.205219344911457895]Search in Google Scholar
[50. Galkina E and Ley K. Vascular adhesion molecules in atherosclerosis. Arterioscler Thromb Vasc Biol. 2007;27:2292-301.10.1161/ATVBAHA.107.14917917673705]Search in Google Scholar
[51. Paez A, Mendez-Cruz AR, Varela E, et al. HUVECs from newborns with a strong family history of myocardial infarction overexpress adhesion molecules and react abnormally to stimulating agents. Clin Exp Immunol. 2005;141:449-58.10.1111/j.1365-2249.2005.02858.x180947016045734]Search in Google Scholar
[52. Davies MJ, Gordon JL, Gearing AJ, et al. The expression of the adhesion molecules ICAM-1, VCAM-1, PECAM, and E-selectin in human atherosclerosis. J Pathol. 1993;171:223-9.10.1002/path.17117103117506307]Search in Google Scholar
[53. Yu G, Rux AH, Ma P, et al. Endothelial expression of E-selectin is induced by the platelet-specific chemokine platelet factor 4 through LRP in an NF-kappaB-dependent manner. Blood. 2005;105:3545-51.10.1182/blood-2004-07-2617189502415591119]Search in Google Scholar
[54. Hafezi-Moghadam A, Thomas KL, Prorock AJ, et al. L-selectin shedding regulates leukocyte recruitment. J Exp Med. 2001;193:863-72.10.1084/jem.193.7.863]Search in Google Scholar
[55. del Pozo MA, Pulido R, Munoz C, et al. Regulation of ICAM-3 (CD50) membrane expression on human neutrophils through a proteolytic shedding mechanism. Eur J Immunol. 1994;24:2586-94.10.1002/eji.1830241104]Search in Google Scholar
[56. Kostidou E, Topouridou K, Daniilidis A, et al. Oxidized laminin-1 induces increased monocyte attachment and expression of ICAM-1 in endothelial cells. Int J Exp Pathol. 2009;90:630-7.10.1111/j.1365-2613.2009.00686.x]Search in Google Scholar
[57. Matheny HE, Deem TL, Cook-Mills JM. Lymphocyte migration through monolayers of endothelial cell lines involves VCAM-1 signaling via endothelial cell NADPH oxidase. J Immunol. 2000;164:6550-9.10.4049/jimmunol.164.12.6550]Search in Google Scholar
[58. Malik I, Danesh J, Whincup P, et al. Soluble adhesion molecules and prediction of coronary heart disease: a prospective study and meta-analysis. Lancet. 2001;358:971-6.10.1016/S0140-6736(01)06104-9]Search in Google Scholar
[59. Woodfin A, Voisin MB, Nourshargh S. PECAM-1: a multifunctional molecule in inflammation and vascular biology. Arterioscler Thromb Vasc Biol. 2007;27:2514-23.10.1161/ATVBAHA.107.15145617872453]Search in Google Scholar
[60. Wong CW, Wiedle G, Ballestrem C, et al. PECAM-1/CD31 transhomophilic binding at the intercellular junctions is independent of its cytoplasmic domain; evidence for heterophilic interaction with integrin alphavbeta3 in Cis. Mol Biol Cell. 2000;11:3109-21.10.1091/mbc.11.9.31091497910982404]Search in Google Scholar
[61. Mandell KJ, Parkos CA. The JAM family of proteins. Adv Drug Deliv Rev. 2005;57:857-67.10.1016/j.addr.2005.01.00515820556]Search in Google Scholar
[62. Babinska A, Azari BM, Salifu MO, et al. The F11 receptor (F11R/JAM-A) in atherothrombosis: overexpression of F11R in atherosclerotic plaques. Thromb Haemost. 2007;97:272-81.10.1160/TH06-08-0454]Search in Google Scholar
[63. Ostermann G, Fraemohs L, Baltus T, et al. Involvement of JAM-A in mononuclear cell recruitment on inflamed or atherosclerotic endothelium: inhibition by soluble JAM-A. Arterioscler Thromb Vasc Biol. 2005;25:729-35.10.1161/01.ATV.0000157154.14474.3b15681301]Search in Google Scholar
[64. Zernecke A, Liehn EA, Fraemohs L, et al. Importance of junctional adhesion molecule-A for neointimal lesion formation and infiltration in atherosclerosis-prone mice. Arterioscler Thromb Vasc Biol. 2006;26:e10-3.10.1161/01.ATV.0000197852.24529.4f]Search in Google Scholar
[65. Keiper T, Al-Fakhri N, Chavakis E, et al. The role of junctional adhesion molecule-C (JAM-C) in oxidized LDL-mediated leukocyte recruitment. FASEB J. 2005;19:2078-80.10.1096/fj.05-4196fje]Search in Google Scholar
[66. Weitz-Schmidt G. Lymphocyte function-associated antigen-1 blockade by statins: molecular basis and biological relevance. Endothelium. 2003;10:43-7.10.1080/10623320303360]Search in Google Scholar
[67. Welzenbach K, Hommel U, Weitz-Schmidt G. Small molecule inhibitors induce conformational changes in the I domain and the I-like domain of lymphocyte function-associated antigen-1. Molecular insights into integrin inhibition. J Biol Chem. 2002;277:10590-8.10.1074/jbc.M110521200]Search in Google Scholar
[68. Romano M, Mezzetti A, Marulli C, et al. Fluvastatin reduces soluble P-selectin and ICAM-1 levels in hypercholesterolemic patients: role of nitric oxide. J Investig Med. 2000;48:183-9.]Search in Google Scholar
[69. Seljeflot I, Tonstad S, Hjermann I, et al. Reduced expression of endothelial cell markers after 1 year treatment with simvastatin and atorvastatin in patients with coronary heart disease. Atherosclerosis. 2002;162:179-85.10.1016/S0021-9150(01)00696-7]Search in Google Scholar
[70. Rezaie-Majd A, Maca T, Bucek RA, et al. Simvastatin reduces expression of cytokines interleukin-6, interleukin-8, and monocyte chemoattractant protein-1 in circulating monocytes from hypercholesterolemic patients. Arterioscler Thromb Vasc Biol. 2002;22:1194-9.10.1161/01.ATV.0000022694.16328.CC]Search in Google Scholar
[71. Izidoro-Toledo TC, Guimaraes DA, Belo VA, et al. Effects of statins on matrix metalloproteinases and their endogenous inhibitors in human endothelial cells. Naunyn Schmiedebergs Arch Pharmacol. 2011;383:547-54.10.1007/s00210-011-0623-0]Search in Google Scholar
[72. Franzoni F, Quinones-Galvan A, Regoli F, et al. A comparative study of the in vitro antioxidant activity of statins. Int J Cardiol. 2003;90:317-21.10.1016/S0167-5273(02)00577-6]Search in Google Scholar
[73. Davignon J, Jacob RF, Mason RP. The antioxidant effects of statins. Coron Artery Dis. 2004;15:251-8.10.1097/01.mca.0000131573.31966.3415238821]Search in Google Scholar
[74. Lim S, Barter P. Antioxidant effects of statins in the management of cardiometabolic disorders. J Atheroscler Thromb. 2014;21:997-1010.10.5551/jat.2439825132378]Search in Google Scholar
[75. Antoniades C, Bakogiannis C, Tousoulis D, et al. Preoperative atorvastatin treatment in CABG patients rapidly improves vein graft redox state by inhibition of Rac1 and NADPH-oxidase activity. Circulation. 2010;122:S66-73.10.1161/CIRCULATIONAHA.109.927376]Search in Google Scholar
[76. Antoniades C, Bakogiannis C, Leeson P, et al. Rapid, direct effects of statin treatment on arterial redox state and nitric oxide bioavailability in human atherosclerosis via tetrahydrobiopterinmediated endothelial nitric oxide synthase coupling. Circulation. 2011;124:335-45.10.1161/CIRCULATIONAHA.110.985150]Search in Google Scholar
[77. Antonopoulos AS, Margaritis M, Shirodaria C, et al. Translating the effects of statins: from redox regulation to suppression of vascular wall inflammation. Thromb Haemost. 2012;108:840-8.10.1160/TH12-05-0337]Search in Google Scholar
[78. de Lemos JA, Blazing MA, Wiviott SD, et al. Early intensive vs a delayed conservative simvastatin strategy in patients with acute coronary syndromes: phase Z of the A to Z trial. JAMA. 2004;292:1307-16.10.1001/jama.292.11.1307]Search in Google Scholar
[79. Officers A, Coordinators for the ACRGTA, Lipid-Lowering Treatment to Prevent Heart Attack T. Major outcomes in moderately hypercholesterolemic, hypertensive patients randomized to pravastatin vs usual care: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT-LLT). JAMA. 2002;288:2998-3007.10.1001/jama.288.23.2998]Search in Google Scholar
[80. Sever PS, Dahlof B, Poulter NR, et al. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial--Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet. 2003;361:1149-58.10.1016/S0140-6736(03)12948-0]Search in Google Scholar
[81. Kjekshus J, Apetrei E, Barrios V, et al. Rosuvastatin in older patients with systolic heart failure. N Engl J Med. 2007;357:2248-61.10.1056/NEJMoa0706201]Search in Google Scholar
[82. Heart Protection Study Collaborative G. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet. 2002;360:7-22.10.1016/S0140-6736(02)09327-3]Search in Google Scholar
[83. Ridker PM, Danielson E, Fonseca FA, et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med. 2008;359:2195-207.10.1056/NEJMoa080764618997196]Search in Google Scholar
[84. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. N Engl J Med. 1998;339:1349-57.]Search in Google Scholar
[85. Shepherd J, Cobbe SM, Ford I, et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. N Engl J Med. 1995;333:1301-7. 10.1056/NEJM1995111633320017566020]Search in Google Scholar